# Pediatric Obesity Pharmacotherapy Selector > Select the right pharmacologic agent for a child aged 12+ with obesity using the CMAJ 2025 guideline — choosing between GLP-1 receptor agonists, metformin, or orlistat with monitoring guidance. Trigger when a clinician asks which medication to use for pediatric obesity, whether to start semaglutide or metformin in a child, or how to manage obesity pharmacologically in adolescents. - Skill: `dromlakhani/pediatric-obesity-pharmacotherapy-selector` (Agent Skill) - Install (CLI): `npx skillmds@latest add dromlakhani/pediatric-obesity-pharmacotherapy-selector` - Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/pediatric-obesity-pharmacotherapy-selector/raw - Safety review: pending (external: skill-scanner PASS, skillspector PASS) - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: AI & ML - Author: dromlakhani (https://skillmd.com/u/dromlakhani) - Updated: 2026-09-08 - Page: https://skillmd.com/skills/dromlakhani/pediatric-obesity-pharmacotherapy-selector --- # Pediatric Obesity: Pharmacotherapy Selector Step-by-step guide to selecting and initiating pharmacotherapy in children ≥12 years with obesity. All agents must be combined with behavioural and psychological interventions. Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456). --- ## Step 1 — Confirm Eligibility Before prescribing, confirm all three: | Check | Criteria | |---|---| | Age | ≥ 12 years (no evidence for < 12) | | Diagnosis | Obesity confirmed (BMIz using WHO/Canadian charts) | | Behavioural program | Currently enrolled or starting alongside medication | > ⚠️ **Pharmacotherapy must always be co-prescribed with behavioural and psychological interventions.** Medication alone is not recommended. --- ## Step 2 — Assess Contraindications and Preferences Before selecting an agent, screen for: - **GI conditions** (IBD, gastroparesis) — caution with GLP-1RAs - **Eating disorder** (binge eating, atypical anorexia) — psychiatric clearance before any pharmacotherapy - **Renal or hepatic impairment** — affects metformin dosing - **Family access and affordability** — GLP-1RAs are costly; metformin widely available - **Patient/family values** — injection vs. oral, frequency, side effect tolerability --- ## Step 3 — Select Agent ### Option A — GLP-1 Receptor Agonists (Preferred where accessible) *Semaglutide, liraglutide, exenatide* **Conditional recommendation; very low to low certainty** **Best for:** Significant BMIz reduction needed; cardiometabolic comorbidities (hypertension, dyslipidaemia, insulin resistance) **Evidence:** - BMIz: small to large reduction (semaglutide has largest effect — very large effect on BMIz; 1 RCT, 201 children aged 12–17) - HRQoL: small benefit (semaglutide); little/no effect for others - Triglycerides: large benefit (semaglutide); small for others - HDL-C, LDL-C, total cholesterol, systolic BP: small benefit (semaglutide) **Common AEs (important — discuss upfront):** - GI: nausea, diarrhea, vomiting, abdominal pain (most common; 79% semaglutide vs. 82% placebo — many are trivial and self-limiting) **Serious AEs (uncertain risk):** - Cholelithiasis, appendicitis (11% semaglutide vs. 9% placebo in key RCT) - Risk appears similar to control groups but uncertain — monitor **Semaglutide note:** Stronger evidence than liraglutide/exenatide based on current data, but guideline recommends GLP-1RAs as a class due to limited paediatric RCTs. --- ### Option B — Biguanides (Metformin) *Good first option, especially if GLP-1RAs unavailable or unaffordable* **Conditional recommendation; low to moderate certainty** **Best for:** Insulin resistance present; oral route preferred; cost/access barrier to GLP-1RAs **Evidence:** - BMIz: moderate reduction - Cardiometabolic: small benefits on lipids and insulin resistance - HRQoL, anxiety, depression: little to no effect **AEs:** - No serious AEs reported in paediatric studies - Mild-moderate GI (nausea, diarrhea) — more than placebo but manageable; start low and titrate - Not associated with increased serious AEs (critical safety advantage over GLP-1RAs) --- ### Option C — Lipase Inhibitors (Orlistat) *Use only if A and B are unavailable or contraindicated* **Conditional recommendation; low certainty — least preferred** **Evidence:** Lacks evidence on HRQoL, depression, anxiety. **AEs:** - More serious AEs than control (critically important — higher risk) - More mild-moderate GI AEs (oily stools, faecal urgency, leakage) - Fat-soluble vitamin malabsorption — supplement required > ⚠️ **Avoid as first choice.** Only use if GLP-1RAs and metformin are not feasible. --- ## Step 4 — Initiate and Counsel Before prescribing, cover all three with the child and family: 1. **Expected benefits:** BMIz reduction is likely modest in most (not guaranteed); improvements in cardiometabolic markers; possibly HRQoL 2. **Expected harms:** Discuss the relevant AE profile for the chosen agent 3. **Duration:** Obesity is chronic — medication may be long-term; reassess regularly 4. **What to do if GI side effects occur:** Reassure most are transient; hydration; dose titration strategy --- ## Step 5 — Monitoring Plan Review at **3 months**, then every **6 months**: | Outcome | Why | |---|---| | BMIz | Primary efficacy marker | | HRQoL (PedsQL or similar) | Critically important to families | | Depression & anxiety screening | Critically important — monitor throughout | | BP (systolic and diastolic) | Cardiometabolic target | | Fasting lipids (total cholesterol, LDL-C, HDL-C, TG) | Cardiometabolic benefit expected | | Fasting insulin / HOMA-IR | Insulin resistance marker | | ALT | Hepatic safety (especially GLP-1RAs) | | GI adverse events | Adherence-limiting; especially GLP-1RAs | | Serious AEs (hospitalisation) | Especially cholelithiasis with GLP-1RAs | --- ## Clinical Guardrails - **No pharmacotherapy under 12 years** — no evidence base; do not extrapolate - **Always combine with behavioural program** — medication alone is not guideline-concordant - **Screen for eating disorders before starting** — pharmacotherapy may worsen body image disturbance - **Shared decision-making is mandatory** — especially given low-to-moderate certainty evidence for all agents - **Discontinue if no benefit after adequate trial** (typically 3–6 months) and reassess - **GLP-1RAs are not stepwise** — can be offered alongside or before trying metformin based on clinical picture and family preference --- ## Source CMAJ 2025 Clinical Practice Guideline: *Managing obesity in children.* Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: [10.1503/cmaj.241456](https://doi.org/10.1503/cmaj.241456) Updated version: June 3, 2025.